Literature DB >> 21699644

Multicenter evaluation of the prognostic value of pT0 stage after radical cystectomy due to urothelial carcinoma of the bladder.

Matthias May1, Patrick J Bastian, Maximilian Burger, Christian Bolenz, Lutz Trojan, Edwin Herrmann, Christian Wülfing, Stefan C Müller, Jörg Ellinger, Alexander Buchner, Christian G Stief, Derya Tilki, Wolfgang Otto, Thomas Höfner, Markus Hohenfellner, Axel Haferkamp, Jan Roigas, Mario Zacharias, Wolf F Wieland, Hans-Martin Fritsche.   

Abstract

OBJECTIVE: •To evaluate the characteristics and long-term outcome of patients with pT0 stage after radical cystectomy (RC) for urothelial carcinoma of the urinary bladder (UCB). PATIENTS AND METHODS: •Clinical and pathological records of 2403 patients treated with RC for UCB were collected in a multi-institutional database. •The patients met the following criteria: clinical tumour stage cTa-cT2, cN0, cM0, no neoadjuvant chemotherapy or radiotherapy. •Overall (OS) and cancer-specific survival rates (CSS) were calculated for the various clinical tumour stages in relation to their corresponding pathological tumour stage in the RC sample. •Further to this, a multivariable prediction model was developed based on the available clinical data to estimate the probability of tumour stage pT0.
RESULTS: •The mean follow-up was 53 months and 132 patients (5.5%) were stage pT0. •Patients with stage cT2-pT0 had a 5-year CSS of 87% vs 69% for cT2-pT2 (P= 0.012) and 57% for cT2-pT+ (P < 0.001). •In a multivariable Cox-model, stage pT0 led to a significant reduction of cancer-specific mortality (hazard ratio0.27; 95% confidence interval 0.12-0.61). •A logistical regression model identified clinical tumour stage (advantage for non-invasive stages) and transurethral resection of the urinary bladder (TURB) time frame (advantage for more recent surgery) as independent predictors for stage pT0.
CONCLUSIONS: •In muscle-invasive clinical tumour stages, patients with pathological tumour stage pT0 form a subgroup showing a significantly better CSS. •A radical TURB is, assumedly, not causative of this improved survival rate, but rather it is that individual tumour characteristics allow for complete tumour eradication through the TURB procedure. •A TURB with R0 resection is, as such, only a sign of a better tumour prognosis.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21699644     DOI: 10.1111/j.1464-410X.2011.10189.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Accurate determination of the pathological stage with gross dissection protocol for radical cystectomy.

Authors:  Farkas Sükösd; Béla Iványi; László Pajor
Journal:  Pathol Oncol Res       Date:  2014-02-23       Impact factor: 3.201

Review 2.  [Structure of biobanks for urological research].

Authors:  G Hatiboglu; J Huber; E Herpel; I V Popeneciu; J Nyarangi-Dix; D Teber; B A Hadaschik; S Pahernik; S Duensing; M Hohenfellner
Journal:  Urologe A       Date:  2015-09       Impact factor: 0.639

3.  [Transitional cell carcinoma of the bladder: bladder-sparing therapy].

Authors:  F Vom Dorp; S Tschirdewahn; T Szarvas; H Rübben; R Kraemer; C Rehme
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

4.  Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011.

Authors:  Matthias May; Hans-Martin Fritsche; Malte W Vetterlein; Patrick J Bastian; Michael Gierth; Philipp Nuhn; Atiqullah Aziz; Margit Fisch; Christian G Stief; Markus Hohenfellner; Manfred P Wirth; Vladimir Novotny; Oliver W Hakenberg; Joachim Noldus; Christian Gilfrich; Christian Bolenz; Maximilian Burger; Sabine D Brookman-May
Journal:  World J Urol       Date:  2016-06-14       Impact factor: 4.226

5.  Curative Effect and Survival Assessment Comparing Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin and Cisplatin as Neoadjuvant Therapy for Bladder Cancer: A Systematic Review and Meta-Analysis.

Authors:  Tiange Wu; Yuqing Wu; Shuqiu Chen; Jianping Wu; Weidong Zhu; Hui Liu; Ming Chen; Bin Xu
Journal:  Front Oncol       Date:  2021-11-25       Impact factor: 6.244

6.  Outcomes and Prognostic Factors of Patients with Urothelial Carcinoma Undergoing Radical Cystectomy and pT0 in the Final Histology Without Neoadjuvant Chemotherapy.

Authors:  Severin Rodler; Alexander Buchner; Lennert Eismann; Gerald Bastian Schulz; Julian Marcon; Stephan Ledderose; Boris Schlenker; Christian G Stief; Alexander Karl; Jan-Friedrich Jokisch
Journal:  Res Rep Urol       Date:  2022-08-01

7.  Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer and Its Impact on Surgical Morbidity and Oncological Outcomes: A Real-World Experience.

Authors:  Thanh-Tuan Nguyen; Olivier Huillard; Yohann Dabi; Julien Anract; Mathilde Sibony; Marc Zerbib; Evanguelos Xylinas
Journal:  Front Surg       Date:  2018-09-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.